Abstract:
:The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some improvement has been made for acute lymphoblastic leukemia (ALL). Emerging new treatment modalities, such as immunotherapy, are now beginning to be available for acute leukemia, mostly for patients suffering from ALL. This review aims to give an overview of these new therapeutic approaches, especially those already available. The focus is on cell-based immunotherapy, or molecules using preexisting host cells. Underlying mechanisms are explained and an overview of clinical experience with phase 1-3 studies is given. Immunotherapies discussed are antibody-drug conjugates, bispecific T-cell engagers (BiTEs), chimeric antigen receptor T cells (CARTs) and immune checkpoint inhibitors (ICPIs). Most of the clinical studies reviewed are in ALL patients, usually in the relapse setting, but where available, studies on AML patients were also considered. This new general treatment approach offers hope to patients with until now dismal clinical outcome. Hopes are high that future developments, and moving these therapies to an earlier treatment phase, will improve the prognosis of patients suffering from acute leukemia.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Blum S,Martins F,Lübbert Mdoi
10.1016/j.leukres.2017.06.011subject
Has Abstractpub_date
2017-09-01 00:00:00pages
63-73eissn
0145-2126issn
1873-5835pii
S0145-2126(17)30464-2journal_volume
60pub_type
杂志文章,评审abstract::Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2005.10.025
更新日期:2006-07-01 00:00:00
abstract::The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic malignancies characterized by ineffective hematopoiesis, progressive bone marrow (BM) failure, cytogenetic and molecular abnormalities, and variable risk of progression to acute myeloid leukemia (AML). The BM microenvironment in MDS plays ...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2015.06.017
更新日期:2015-10-01 00:00:00
abstract:PURPOSE:The study aims to develop a prognostic scoring system based on prognostic lncRNAs for acute myeloid leukemia (AML). METHODS:Based on lncRNA expression profiles downloaded from The Cancer Genome Atlas (TCGA), differentially expressed long noncoding RNAs (DELs) between good prognosis and bad prognosis samples we...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2019.106261
更新日期:2020-01-01 00:00:00
abstract::Expression of cell cycle-regulating genes was studied in human myeloid leukemia cell lines ML-1, ML-2 and ML-3 during induction of differentiation in vitro. Myelomonocytic differentiation was induced by phorbol ester (12-o-Tetradecanoyl-phorbol-13-acetate, TPA), tumor necrosis factor alpha (TNFalpha) or interferon gam...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(03)00103-6
更新日期:2003-12-01 00:00:00
abstract::Little information is available about the risk factors and means to improve the survival rate of acute leukemia in a rare but often fatal complication after liver transplantation (LT). We report the development of AML-M2 in one of the 764 patients who underwent liver transplantation at our center, and review the liter...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.03.035
更新日期:2009-10-01 00:00:00
abstract::Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with "peripheral T-cell lymphoma, unspecified" diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin. According to the IPI, 72.2% were categorize...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.04.016
更新日期:2004-12-01 00:00:00
abstract::The use of low density lipoprotein (LDL) as drug carrier in acute myeloblastic leukemia chemotherapy is attractive due to high LDL uptake by leukemic cells. Lipid-based formulations, such as liposomes or microemulsions are promising alternatives. In the current study, we incorporated N-trifluoroacetyl-adriamycin-14-va...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.06.012
更新日期:2006-02-01 00:00:00
abstract::The chemicals 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of acute lymphoblastic leukemia. The intracellular metabolism of 6-MP to 6-thioguanosine nucleotides (TGN) via 6-thioinosine 5'-monophosphate (TIMP) is crucial for its cytotoxic effect. MTX inhibits purine de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90065-f
更新日期:1992-01-01 00:00:00
abstract::Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/U...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1016/j.leukres.2018.08.022
更新日期:2018-10-01 00:00:00
abstract::The effect of VM-26, a topoisomerase II targeting drug, on IW32 murine erythroleukemia cells was investigated. The VM-26 induced IW32 cells to differentiate at a non-toxic but cytostatic concentration (0.01 microgram/ml). More than 40% of the cells were induced to synthesize hemoglobin, and cells were arrested in G2/M...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(95)00144-1
更新日期:1996-03-01 00:00:00
abstract::Homeobox genes HOXA9 and MEIS1 are evolutionarily conserved transcription factors with essential roles in both hematopoiesis and leukemogenesis. They act as dominant cooperating oncoproteins that cause acute leukemias bearing MLL translocations and to a lesser extent T-cell acute lymphocytic leukemia (ALL) characteriz...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.04.012
更新日期:2015-08-01 00:00:00
abstract::The role of hemin induction of K562 in inositol phospholipid metabolism has not been previously studied. K562 cells were induced to synthesize hemoglobin upon addition of bovine hemin to the culture media. The phospholipid content of K562 was determined before and after the addition of hemin. The results of this study...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90055-x
更新日期:1991-01-01 00:00:00
abstract::The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KITwt); and AML wi...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2017.12.012
更新日期:2018-02-01 00:00:00
abstract::MicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the post-transcriptional level through its sequence complementation with target mRNAs. An individual miRNA species can simultaneously influence the expression of multiple genes and conversely, several miRNAs can synchronously contro...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2013.08.020
更新日期:2013-11-01 00:00:00
abstract::This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.08.009
更新日期:2009-04-01 00:00:00
abstract::2',5'-oligoadenylate synthetase (OAS) has been implicated in the effects of interferons (INF) and steroid hormones on cell growth and differentiation. We studied the combined effects in vitro of hormones and INF on OAS activity in cells from 10 patients with chronic lymphocytic leukemia. IFN enhanced OAS activity in a...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(89)90163-x
更新日期:1989-01-01 00:00:00
abstract::In this report we evaluated the exact expression pattern of c-Kit on mobilized peripheral blood (PB) CD34+ cells. Using a monoclonal antibody against CD117 antigen (95C3), flow cytometric analysis revealed that approximately 25% of the mobilized PB CD34+ cells coexpress c-Kit. This cell fraction showed a considerable ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(98)00002-2
更新日期:1998-04-01 00:00:00
abstract::Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2018.11.007
更新日期:2019-01-01 00:00:00
abstract::Leukemic cell apoptosis may be enhanced by appropriate oxidative stress. We report here the mechanism of Jurkat cell apoptosis by monochloramine (NH(2)Cl), a neutrophil-derived oxidant. NH(2)Cl induced caspase-dependent apoptosis, which was preceded by cytochrome c and Smac/Diablo release from mitochondria. Within 10m...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.07.009
更新日期:2009-01-01 00:00:00
abstract::Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at a...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2012.08.006
更新日期:2012-12-01 00:00:00
abstract::Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outco...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2009.04.036
更新日期:2010-02-01 00:00:00
abstract::In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(94)00118-t
更新日期:1995-01-01 00:00:00
abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2020.106385
更新日期:2020-08-01 00:00:00
abstract::Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD). This gene is considered as a member of cancer-testis (CT) genes. We previously demonstrated TSGA10 ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.11.012
更新日期:2006-07-01 00:00:00
abstract::Of 417 cases of chronic lymphocytic leukaemia (CLL) examined morphologically, 346 (83%) showed low (less than 10%) numbers of cells with prolymphocytoid (PLC) morphology. Immunological studies in 267 of these cases, with particular reference to membrane surface immunoglobulin (SIg) densities and FMC7 expression, revea...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90018-x
更新日期:1987-01-01 00:00:00
abstract::In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins. Lung resistance-related protein (LRP), multidrug resistance-associated protein and P-glycoprotein are three MD...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.10.012
更新日期:2007-04-01 00:00:00
abstract::Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.01.014
更新日期:2008-08-01 00:00:00
abstract::We conducted an analysis of the effect of monocytosis at diagnosis of CLL on subsequent overall (OS) and treatment-free survival (TFS). Monocyte counts were performed using the Sysmex XE2100 analyser. A monocyte count >0.9 × 10(9)L(-1) at the time of diagnosis was associated with a shortened OS and TFS. Monocytosis at...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.02.020
更新日期:2013-06-01 00:00:00
abstract::The effect of serum on the proliferation of human bone marrow pluripotent progenitor cells (CFU-GEMM), was compared to that of fresh frozen plasma (FFP). Serum significantly increased the number of mixed erythroid-granulocytic-megakaryocytic colonies (CFU-GEMM) and erythrocytic bursts (BFU-E) in this assay system (p l...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(85)90062-1
更新日期:1985-01-01 00:00:00
abstract::The association between seven polymorphisms in the genes hOCT1 and MDR1, encoding for imatinib transporter proteins, and the response to imatinib 400mg/daily was investigated in 65 patients newly diagnosed with chronic-phase chronic myeloid leukemia. The AA genotype at the rs6935207 hOCT1 polymorphic locus was not det...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.12.004
更新日期:2011-08-01 00:00:00